Key findings: Prescribing trends Using a subset of Truveta Data, Truveta Research identified people who were prescribed a GLP-1 RA between January 01, 2018 and September 30, 2025
At 1000-2000mg daily, taken with a carbohydrate-containing meal and alongside consistent exercise, it can be a reasonable, low-risk addition for the right person but it is not a universal fat-loss solution
Ectopic expression of BAF53A can promote proliferation, colony formation, and tumor development in CRC cells, whereas knocking down BAF53A impairs these cellular functions
Higher relative amounts of DCI may impair oocyte quality, even while supporting insulin signaling elsewhere in the body
The starting dose of 4 units (approximately 0.20 mg) sits below the typical 0.25 mg starting point, which may help patients who are particularly sensitive to GLP-1 side effects
USA 94 , 50455049 (1997) N